Table 3.

Selected reports evaluating common primary tumor acquisition methods in NSCLC

Author, year of publication	Type of study	N	Procedure used	Type of tissue obtained	Molecular analyses carried out	Complications	Successful molecular analysis
Gill et al. 2012 [11]a	Single- institution retrospective review	81	CT-guided TTNB	Formalin-fixed paraffin embedded (FFPE)	PCR-sanger sequencing for hotspot mutations: EGFR, KRAS, BRAF, PIK3CA HER2; FISH: ALK	Pneumothorax: 23 (28.3%)	Sequencing: 64 (79%)
						Chest tube: 6 (7%)	FISH: 60 (71%)
						Hospitalization: 9 (11%)
						Intra-parenchymal hemorrhage: 19 (23%)
						18 grade1; 1 grade 2
Solomon et al. 2010 [9]	Selected consecutive patients from a phase II single-institution trial	18	CT or fluoroscopy guided TTNB	FFPE	EGFR by direct sequencing or PCR; KRAS by direct sequencing	Pneumothorax: 3 (17%)	16 (89%)
						No chest tube placement or hospitalization
Cheung et al. 2010 [10]	Retrospective review	47	CT-guided TTNB	Fresh frozen	EGFR by PCR	Pneumothorax: 6 (13%)	47 (100%)
						Chest tube: 2%
						Hospitalization NR
						Hemoptysis: 3 (6%)
Reck et al. 2011 [8]	Multicenter phase II trial	255	Bronchoscopic biopsy	Fresh frozen	Gene expression profiling	NR	122 (48%)

^aAbstract only.

NSCLC, non-small-cell lung cancer; N, number of patients; CT, computed tomography; TTNB, transthoracic needle biopsy; FFPE, formalin-fixed paraffin embedded; PCR, polymerase chain reaction; FISH, fluorescence in situ hybridization; NR, not reported.